Where the science of curing Type 1 diabetes actually stands: islet and stem-cell therapies, beta-cell regeneration, immunotherapies, and disease-modifying trials, in plain language.
Newest public articles in this topic cluster.
Highest growth-index pieces and decision-engine promote picks — still evidence-labeled, not medical advice.
Scientists are exploring ways to replace insulin-producing cells using new technologies and cellular therapies. While early results show promise, these approaches are still in early testing phases.
New research reveals that pancreatic alpha and beta cells have fundamentally different defenses against immune attack. Understanding these differences could point to new ways to protect insulin-producing beta cells.
Researchers are developing treatments designed to preserve or restore the pancreas's ability to produce insulin by protecting beta cells from immune attack. These therapies aim to change the course of Type 1 diabetes at any stage of the disease.
For a century, insulin has been the lifeline for people with Type 1 diabetes. Now, researchers are working on immunotherapies designed to preserve the body's remaining insulin production—potentially making diabetes easier to manage.
Disease-modifying therapies aim to slow or stop Type 1 diabetes before symptoms appear. JDRF researchers are connecting screening efforts with clinical testing to make these treatments available to people in early stages of the disease.
Scientists are making progress on stem cell therapies that could restore insulin production in Type 1 diabetes. But major hurdles remain before these treatments become widely available.
A new clinical trial has generated interest in the Type 1 diabetes community. Here's what we know about the approach, its potential, and the realistic picture of where it stands.
Researchers are working to create insulin-producing cells from stem cells in early clinical trials. Here's what the emerging research shows and what we still need to learn.
Early human trials suggest gene-edited insulin-producing cells can work without immunosuppression drugs. Researchers are now focused on whether these cells can survive and function for years in the body.
The first treatment designed to slow type 1 diabetes progression has been approved for use in England and Wales. Here's what you need to know about who can access it and what the evidence shows.
Early results from a clinical trial show that a cell therapy called zimislecel enabled most patients to stop taking insulin injections. Researchers are working toward regulatory approval as they continue studying the approach.
A new stem cell therapy called zimislecel is being tested as a potential treatment that could help the body produce its own insulin again. While early clinical trial results are encouraging, researchers emphasize this represents one step forward in a longer research journey.
A major international study tested whether giving high-dose oral insulin to babies at genetic risk could stop Type 1 diabetes before it starts. The trial did not meet its primary endpoint — here is what it found and what remains open.
Researchers are exploring pig islet transplants as a potential solution to the shortage of human donor cells. Early studies show promise, but significant challenges remain before this approach becomes available to patients.
For decades, researchers believed that once insulin-producing beta cells were destroyed in Type 1 diabetes, they were gone for good. New evidence suggests the picture is far more complex—and opens doors to transformative therapies.
For decades, researchers believed that lost beta cells could never come back. New work is challenging that assumption and exploring whether the body's own cells might be coaxed to regrow.
Scientists are studying how the body might regenerate insulin-producing cells. Here's what current research is exploring—and why it matters.
New research reveals that insulin-producing beta cells may actively contribute to Type 1 diabetes development before the immune system ever attacks them. Understanding these early failures could open new avenues for prevention.
Teplizumab (Tzield) is now available in the UK for children aged 8 and older and adults in early-stage Type 1 diabetes. The drug can delay progression to symptomatic diabetes by around 3 years on average.
New treatments aim to stop the immune system from attacking insulin-producing cells. Researchers are testing immunotherapies at different stages—before diabetes develops, right after diagnosis, and beyond.
Researchers found that engineered scaffolds made from pancreatic tissue may help transplanted insulin-producing cells work effectively without requiring immune-suppressing drugs. The findings could open new possibilities for treating Type 1 diabetes.
Tzield (teplizumab) was approved in Canada in May 2025 as the first medicine designed to delay Type 1 diabetes onset. However, major drug coverage decisions have created access challenges for Canadian patients.
Early results from a clinical trial suggest tegoprubart may offer a safer alternative to standard immunosuppressive drugs for people receiving islet cell transplants. The drug allowed transplant recipients to achieve insulin independence while avoiding some serious side effects.
A small clinical trial published in the New England Journal of Medicine found that lab-grown stem cells engineered to produce insulin helped most participants reduce or eliminate their daily insulin injections. Researchers say the results signal progress toward cell replacement therapies, though significant hurdles re…
A major review of clinical trials shows that immunotherapy may improve blood sugar control in children recently diagnosed with Type 1 diabetes. These treatments don't replace insulin, but they target the autoimmune process driving the disease.
Researchers are developing a new strategy that uses engineered immune cells to protect transplanted insulin-producing cells from attack. This approach could help cell replacement therapies work better for people with type 1 diabetes.
A pediatric endocrinologist discusses what we know about immunotherapy approaches for children who show early signs of developing Type 1 diabetes. Learn what the research landscape currently looks like and why early intervention matters.
A long-time insulin pen user tested the Omnipod 5 automated insulin pump system for over two months. Here's what they learned about the technology's strengths, limitations, and real-world challenges.
A new treatment called teplizumab can delay the onset of Type 1 diabetes in people at high risk. Here's what the evidence shows about how it works and what it means for patients and families.
If type 1 diabetes runs in your family, your risk is significantly higher. Early screening through a simple blood test may help identify the condition before insulin becomes necessary.
New evidence suggests that beta cells may not be permanently damaged in early Type 2 diabetes. Early action through lifestyle changes may help restore some pancreatic function.
Researchers are developing new ways to create insulin-producing cells from stem cells that work in the laboratory and in animal models. While still in early clinical testing, this approach could one day offer a new treatment option for people with Type 1 diabetes.
Scientists are investigating whether stem cells harvested from fat tissue could help reduce insulin dependence and support pancreatic cell survival in people with Type 1 diabetes. Early results from animal studies and clinical trials are encouraging, but significant work remains.
Researchers in the Netherlands report early success using stem cells to create insulin-producing cells for transplantation. While results are encouraging, scientists emphasize the need for further research before this becomes a standard treatment.
Two experimental treatments are being tested to slow or prevent beta cell damage in people with newly diagnosed Type 1 diabetes. Early results suggest these approaches may be safer and better tolerated than previously available options.
Researchers are exploring a new class of molecules designed to retrain immune cells that attack beta cells. Here's what we know about this early-stage approach.
New data from a University of Chicago study shows that an experimental immunotherapy called tegoprubart may offer a safer alternative to standard anti-rejection drugs in islet cell transplants for Type 1 diabetes.
A newly appointed researcher at Canada's Breakthrough T1D Centre of Excellence will investigate biomarkers that could help predict who will develop type 1 diabetes and how well they'll respond to emerging therapies.
New research suggests insulin-producing beta cells aren't just passive targets of immune attack—they may actively influence whether and how Type 1 diabetes develops through their own internal stress responses.
New research reviews clinical trials of cell-based treatments designed to replace insulin-producing cells damaged by Type 1 diabetes. While early results are encouraging, scientists still need to solve several technical hurdles before these therapies become widely available.
Breakthrough T1D is expanding its focus on early detection, immunotherapy, and cell replacement approaches—all of which depend on people willing to participate in research studies.
Sierra's story shows why knowing your family history of Type 1 diabetes can lead to early screening and access to therapies that may delay disease onset.
A new study from USC suggests people with type 1 diabetes may face increased risk for bladder cancer. Researchers are working to understand why this connection exists.
Scientists are growing insulin-producing cells from stem cells to study Type 1 diabetes and develop potential transplant therapies. Recent clinical progress shows these lab-grown islets may one day offer a more permanent treatment option.
New clinical guidelines highlight how screening for early signs of Type 1 diabetes and emerging immunotherapy treatments are helping delay disease onset in at-risk children. Understanding these advances can help families make informed decisions about their care.
A major safety review of immunotherapy trials spanning up to 18 years found no increased risks from experimental type 1 prevention treatments. The findings clear the path for continued research into delaying disease onset.
A bill in Congress could change how insulin-producing islet cell transplants are regulated in the US. Here's what the proposal aims to do and why it matters to the Type 1 community.
A new study in diabetic rats found that berberine, a compound from a traditional medicinal plant, reduced blood sugar and showed signs of restoring damaged pancreatic cells. These early findings suggest a potential avenue for research, though human studies are still needed.
Recent studies suggest that many beta cells in type 2 diabetes may not be permanently dead, but rather inactive. Understanding this distinction could reshape how we think about the disease.
A YouTube video promoting stem cell therapy for diabetes lacks the scientific evidence needed to evaluate its effectiveness. Here's what you should know about assessing unproven treatments.
Hannah Robinson became the first adult in the UK to access teplizumab, an immunotherapy that can delay the progression of early-stage type 1 diabetes. Her story offers insight into what this emerging treatment means for people newly diagnosed.
Research suggests all-trans retinoic acid (ATRA) may help preserve insulin-producing cells and calm the immune system in type 1 diabetes. Scientists are now exploring ways to deliver this compound directly to target areas while minimizing side effects.
Scientists are using stem cells to grow insulin-producing beta cells in the lab, offering a potential way to replace cells destroyed by Type 1 diabetes. Early research shows promise, though clinical applications are still years away.
Two children in British Columbia have become the first in Canada to receive Tzield (teplizumab), a treatment designed to delay type 1 diabetes progression in its early stages. This milestone reflects growing momentum in shifting care from managing diabetes to potentially changing its course.
A major matching gift campaign is multiplying the impact of donations to T1D cure research in Canada, while scientists continue developing promising approaches like beta cell replacement devices and improved blood sugar prediction tools.
Scientists analyzing blood samples from hundreds of people newly diagnosed with Type 1 diabetes have identified two distinct immune subtypes that appear to respond better to different immunotherapy approaches. This early discovery could one day help doctors match patients to treatments more effectively.
Researchers transplanted insulin-producing cells grown from stem cells into three people with Type 1 diabetes, marking a significant step toward cell-based therapies. Early results suggest the approach may help restore insulin production, though many questions remain about long-term safety and effectiveness.
A Type 1 diabetic shares her decision to move from insulin pens to an automated pump after 20 years of managing her condition. Her story highlights both the challenges of diabetes management and the practical considerations that led her to explore new technology.
At the American Diabetes Association's 2025 scientific conference, Vertex Pharmaceuticals presented data on zimislecel, an experimental therapy designed to work with the immune system in Type 1 diabetes. The findings add to ongoing research into cell-based approaches for the condition.
Scientists have identified a protein that enhances how the body uses insulin, and early lab work suggests a small peptide derived from it may help improve blood sugar control in Type 1 diabetes.
The first FDA-approved treatment to delay the onset of Type 1 diabetes is changing how doctors approach the disease. Here's what families need to know about screening, staging, and this emerging therapy.
Researchers are exploring nanomedicines, cell regeneration techniques, and transplantation strategies to restore the insulin-producing cells damaged by Type 1 diabetes. Here's what the latest research shows.
A 42-year-old patient received transplanted cells modified with CRISPR gene editing to resist immune attack. Early results suggest the approach may help the body produce insulin again.
New research in mice reveals that omega-3 fatty acids alter gut bacteria in ways that could calm inflammation in the pancreas. Scientists are mapping the microbial and chemical changes involved.
Scientists have identified a protein in immune cells that may play a key role in triggering type 1 diabetes. Blocking this protein in the laboratory prevented diabetes while leaving other parts of the immune system intact.
Scientists combined a plant compound with a common diabetes medication and observed significant growth in insulin-producing cells in a laboratory study. Here's what this early work means for the Type 1 diabetes community.
Researchers are exploring whether transplanted insulin-producing cells could help people with Type 1 diabetes produce their own insulin again. A small early study presented recent results worth understanding.
Researchers found that a naturally occurring molecule called adenosine may help islet cells withstand the stress of transplantation. Early lab results suggest this approach could improve the success of islet transplants for Type 1 diabetes.
Researchers found that tiny cell-derived particles called extracellular vesicles can protect insulin-producing beta cells after transplantation. The finding might eventually simplify how doctors prepare islets for transplant and improve outcomes for patients.
Researchers and organizations are working together to develop manufactured islet cells that could one day restore insulin production in people with type 1 diabetes. Here's what you need to know about these advancing treatments.
A first-in-human study suggests that genetically modified pancreatic cells may be transplanted into Type 1 diabetes patients without requiring immune-suppressing medications. This could make islet cell transplantation safer and more practical for more people.
The FDA has expanded approval of teplizumab (Tzield) to children as young as one year old with stage 2 type 1 diabetes. The decision is based on safety data from a study of very young children receiving the therapy.
Researchers are testing new transplant-based treatments that aim to restore the body's ability to produce insulin. Early results from patients show promise, though these therapies remain in the early stages of development.
A newly established foundation is backing research into genetically modified insulin-producing cells that could potentially prevent transplant rejection without lifelong immunosuppressive drugs. Clinical trials could begin within two to three years.
Researchers are taking unconventional approaches to understanding type 1 diabetes—from reimagining the cellular environment around immune cells to investigating how antioxidants may influence disease risk. Here's what emerging science is revealing.
Teplizumab, an immunotherapy recently approved in the UK, offers a way to delay the progression of type 1 diabetes in people with early-stage disease. Here's what the evidence shows.
A new medication called teplizumab (Tzield) can slow the progression of type 1 diabetes in children and young adults. Here's what families need to know about this disease-modifying therapy.
Recent clinical trials reveal that transplanted insulin-producing cells grown from stem cells can help some people with Type 1 diabetes achieve better blood sugar control. Researchers are testing different approaches to make these treatments safer and more practical.
Researchers have engineered insulin-producing cells that may survive in the body without immunosuppressive drugs. Early results from one patient show promise, but much more research is needed.
Researchers found that most adults develop detectable autoantibodies years—sometimes decades—before Type 1 diabetes is diagnosed. Understanding this timeline could help identify people at risk earlier.
Teplizumab, a drug that slows the immune system's attack on insulin-producing cells, has been licensed by UK regulators. It marks the first immunotherapy approved to delay early-stage type 1 diabetes.
Teplizumab (Tzield) is the first FDA-approved medication designed to delay the progression of Type 1 diabetes in children. Here's what families need to know about how it works and what the research shows.
Researchers are preparing to test an innovative approach that uses a modified virus to deliver insulin-producing genes directly into muscle tissue. The PROGRESS study marks the first clinical trial of its kind for type 1 diabetes.
A new study using stem cell infusion showed promising results in a small group of Type 1 diabetes patients, with most reporting reduced or eliminated insulin requirements. Researchers are working to understand how the approach works and whether findings will hold up in larger trials.
Scientists are exploring different approaches to help people with Type 1 diabetes produce their own insulin or manage related conditions. Here's what early research is showing.
Researchers are exploring several experimental strategies to help the body produce insulin again, from stem cell transplants to improved islet grafting techniques. Here's what the latest research shows.
Scientists have shown that chemicals can prompt beta cells to multiply—a shift from the old belief that these cells couldn't regenerate. Early research into beta cell regeneration could one day lead to new treatment approaches for Type 1 diabetes.
Several companies are developing potential treatments for Type 1 diabetes. Here's what the clinical trial process actually looks like and why it takes years to bring new therapies to patients.
Researchers have successfully transplanted insulin-producing cells into a patient with type 1 diabetes without triggering immune rejection. While early results are modest, the approach represents a meaningful step toward cell-based therapies.
Researchers are making significant progress developing insulin-producing cells from stem cells that can regulate blood sugar in laboratory and animal studies. Early human trials are underway to test whether this approach can reduce or eliminate the need for insulin injections.
A new monoclonal antibody treatment can delay the progression of type 1 diabetes in children, giving families more time before insulin dependence becomes necessary. Here's what you need to know about this first-of-its-kind therapy.
The approval of teplizumab (Tzield) for children ages one and older marks the first time a disease-modifying therapy is available to address the underlying autoimmune process in very young children with stage 2 type 1 diabetes.
Researchers developed insulin-producing stem cell spheroids that improved blood sugar control and reduced inflammation in diabetic mice without permanently altering genes. The approach works indirectly, suggesting a new avenue for Type 1 diabetes treatment.
Scientists at Scripps Research have discovered a biological mechanism that could open new avenues for preventing and treating type 1 diabetes. The finding points toward potential interventions earlier in the disease process.
A medication has been approved to delay Type 1 diabetes onset. Here's what that means and how researchers are building on this progress.
Scientists are exploring multiple approaches to address the root cause of Type 1 diabetes, including immune system resets, stem cell-derived insulin-producing cells, and improved monitoring of people at risk. While early results in animal studies are promising, researchers emphasize these are still years away from wid…
Researchers are using genetically modified cells derived from stem cells to create insulin-producing cells that can evade the immune system's attack. Early results from one patient show promise, though much more research is needed.
Vertex Pharmaceuticals is testing an approach that replaces damaged insulin-producing cells. Early participants have achieved insulin independence, but the therapy is still new and requires careful monitoring.
A small study shows that CGM data could reveal whether teplizumab is working weeks or months before standard blood tests do. Researchers are now investigating whether this insight might improve how we monitor the drug's impact in children with early-stage Type 1 diabetes.
Scientists are advancing stem cell therapies that can produce insulin-making cells for transplant. Early results show some patients achieved insulin independence, but significant challenges remain before this approach becomes widely available.
A new clinical trial tested whether insulin-producing cells from specially bred pigs could be safely transplanted into people with Type 1 diabetes. Early results suggest the approach may be viable, though more research is needed.
Recent research shows that insulin-producing beta cells' own stress responses—not just immune system attacks—play a central role in Type 1 diabetes. This discovery is reshaping how scientists think about prevention and treatment.
A small clinical trial of stem cell treatment has restored insulin production in participants with Type 1 diabetes. Researchers are exploring whether this approach could reduce or eliminate the need for insulin injections.
A biotech company has published early results from a small group of people who received transplants of laboratory-made beta cells. While outcomes were encouraging, the approach still requires patients to take immunosuppressive medications.
Scientists can now grow insulin-producing islet cells in the laboratory and transplant them into people with Type 1 diabetes. Here's what this emerging research means and what questions remain.
A small biotechnology company called Enselin is testing an early-stage implantable device that combines insulin-producing cells with protective technology. Here's what the first safety results tell us—and what they don't.
Researchers analyzed tiny particles in blood plasma and found a set of proteins that could help predict type 1 diabetes before symptoms appear. The approach identified hundreds of new potential warning signs.
A new study reveals that certain types of immune cells in the pancreas can help beta cells survive and function better—without attacking them. This discovery offers a potential pathway for protecting remaining beta cells in people with Type 1 diabetes.
Scientists are investigating the aryl hydrocarbon receptor (AhR)—a protein found in beta cells—to understand how it responds to diet and environmental factors. Early findings suggest this pathway may play a role in how the body adapts to high-fat diets.
Researchers and clinicians at ATTD 2026 emphasized that detecting type 1 diabetes before symptoms appear could open doors to new treatment options and better outcomes. Widespread screening is now seen as essential to achieving meaningful progress against the disease.
A new cell therapy in clinical trials uses insulin-producing cells from pigs, wrapped in a protective device to shield them from the immune system. If successful, it could eliminate the need for immunosuppressive drugs that current cell therapies require.
A new approach to encapsulating insulin-producing cells has cleared an early safety hurdle in a small Canadian trial. Researchers say the results address a long-standing challenge that has limited similar therapies in the past.
Researchers have successfully transplanted insulin-producing islet cells into the spleen instead of the liver, restoring blood sugar control in animals without requiring heavy immunosuppression. This approach could reduce the burden on patients who rely on islet transplantation to manage Type 1 diabetes.
Researchers have created a bioprinting method that keeps transplanted beta cells alive and functional in the lab for weeks. The advance could help overcome major obstacles in developing cell replacement therapies for Type 1 diabetes.
Researchers are testing immune-based treatments in children at high risk for Type 1 diabetes, aiming to delay or prevent the disease from developing. These early-stage studies represent a shift toward intervening before diagnosis.
Breakthrough T1D Canada highlighted key findings from the ADA's annual conference. Here's what researchers presented about the current state of Type 1 diabetes science.
A new treatment approach shows promise in slowing the decline of insulin-producing cells shortly after type 1 diabetes diagnosis. This may help preserve remaining beta-cell function during the critical early stages of the disease.
Early findings suggest a new cell therapy called zimislecel may help some people with Type 1 diabetes reduce their insulin dependence. Researchers are working to understand how this approach works and who might benefit most.
Doctors at the University of Pennsylvania are investigating how stem cell therapy might help manage type 1 diabetes symptoms. Early research suggests this approach could offer a new avenue for treatment, though more work is needed.
Helmholtz Munich has received funding to investigate how Type 1 diabetes develops in adults, potentially opening new pathways for early detection and intervention.
A biotechnology company is testing a tiny implantable pouch designed to protect insulin-producing cells from the immune system. Early results suggest the approach could help restore insulin production in people with Type 1 diabetes.
Decades of research into regenerating insulin-producing beta cells is reaching patients. New clinical trials show that transplanted stem cell-derived beta cells can restore insulin production and improve blood sugar control in people with Type 1 diabetes.
A clinical trial of transplanted insulin-producing cells delivered directly to the liver has shown encouraging early results, with most recipients producing their own insulin. Researchers are exploring whether this approach could eventually offer an alternative to insulin therapy.
Researchers have discovered signs of type 1 diabetes in umbilical cord blood, opening a path toward earlier screening. The findings suggest the disease process begins during pregnancy, when the body's systems are still developing.
Over a century after insulin was discovered, Type 1 diabetes still causes serious health risks. Scientists are now investigating new ways to calm the immune system, but several obstacles remain.
From transplant breakthroughs to digital tools and caregiver insights, recent research is expanding treatment options and revealing what helps young people manage their condition better.
Researchers developed artificial vesicles derived from tolerogenic dendritic cells that reduced immune attack on pancreatic beta cells in mouse models. The findings suggest this approach could overcome manufacturing challenges of current cell-based immunotherapies.
In November 2022, teplizumab became the first FDA-approved therapy designed to slow the autoimmune process behind type 1 diabetes rather than just manage blood sugar. Clinical trials show it can delay disease progression and preserve the body's ability to produce insulin.
Researchers are testing KRIYA-839, a new approach that teaches muscle cells to produce insulin. Early animal studies showed promising results that lasted years after a single treatment.
Researchers have developed a new method to create insulin-producing cells from stem cells that successfully restored blood sugar control in mice. The advance represents a step forward in exploring cell replacement as a potential future treatment for Type 1 diabetes.
A new literature review examines claims that low-carb diets can prolong remission in Type 1 diabetes. Here's what researchers found—and what remains unknown.
The FDA-approved drug Tzield (teplizumab) is expanding access to delay the onset of stage 3 type 1 diabetes in children as young as 8 years old who have stage 2 disease. New evidence shows it helps preserve the body's ability to produce insulin.
A major follow-up study tracking thousands of people over nearly two decades found no serious safety concerns with immunotherapy drugs designed to delay type 1 diabetes onset. The results clear the way for further research—though these drugs do not cure or reverse the disease.
A person living with Type 1 diabetes for three decades walks through the practical steps of replacing an Omnipod 5 pod. Here's what the real-world process involves.
Scientists worldwide are investigating whether stem cell research could offer new approaches to Type 1 diabetes. An expert in the field discusses what collaboration and current evidence reveal about this emerging area.
A preclinical study suggests that using multiple strategies together may help slow the advancement of type 1 diabetes. While early-stage research, the findings point to a promising direction for future development.
Researchers are exploring immunotherapy approaches that may help preserve insulin-producing cells and delay the onset of Type 1 diabetes. These efforts represent a significant step in the path toward better treatments, though much work remains.
New research shows that pancreatic beta cells activate different defense mechanisms depending on what's attacking them—whether it's a viral signal or direct DNA damage. Understanding these distinct responses could help researchers develop better ways to protect insulin-producing cells.
A new transplant-based treatment being studied at University of Chicago Medicine is allowing some patients to reduce or stop insulin injections. Early results from three trial participants offer a potential path forward for managing Type 1 diabetes.
Researchers have developed a technique to grow uniform clusters of insulin-producing cells that could be used in transplantation devices. The advance addresses a key challenge in making cell replacement therapy practical for people with Type 1 diabetes.
Scientists at Tech Launch Arizona have created a line of human stem cells engineered to avoid immune detection. If successful in clinical use, this approach could eventually help restore insulin production in people with Type 1 diabetes.
Multiple research teams are working on stem cell approaches that could one day restore the body's ability to produce insulin. While progress is real, experts emphasize we're still years away from a widely available treatment.
Researchers found that a fibrin-based material containing tiny blood vessel fragments helps transplanted insulin-producing cells survive and function better when placed under the skin in diabetic rats.
Researchers in Boston are testing thousands of chemical compounds to find ones that might encourage the body's insulin-producing beta cells to multiply and regrow. While still early-stage, this approach represents a shift in how scientists think about treating Type 1 diabetes.
If type 1 diabetes runs in your family, your risk is significantly higher. A simple blood test can detect the condition long before symptoms appear.
A recently published small study reports that patients who received stem cell therapy were able to go without insulin injections for several months. While early results are encouraging, much more research is needed to understand whether this approach could offer a path forward for people with Type 1 diabetes.
Researchers found that blocking a protein called NAMPT may help protect insulin-producing beta cells from immune attack in Type 1 diabetes. The discovery, made in mice and human tissue, points to a potential new approach for slowing disease progression.
A new study reveals that lab-grown insulin-producing cells respond very differently to low-oxygen conditions than natural islets do. Understanding these differences could help scientists design better transplants for Type 1 diabetes.
A large childhood screening study found that simple blood tests can reliably detect children at risk of Type 1 diabetes long before they become sick. Early identification could help prevent emergency diagnoses and open doors to new treatment options.
Katie's diagnosis with early-stage type 1 diabetes opened a window of opportunity to receive teplizumab, an immunotherapy designed to delay the full development of the condition. Her experience shows how early detection can change the timeline of disease progression.
A new stem cell-derived treatment called zimislecel helped most trial participants reduce or stop insulin injections within a year. Researchers are working to understand whether these results will hold in larger studies.
Researchers have discovered that a key immune molecule called IL-1 helps pancreatic beta cells defend themselves against viruses. Understanding this protective mechanism may shed light on what goes wrong in Type 1 diabetes.
An international research study found that engineered scaffolds made from human pancreatic tissue could help transplanted insulin-producing cells function effectively without requiring immune-suppressing drugs.
The immunosuppressive drug teplizumab can now be used in children ages 8 and older shortly after a Type 1 diabetes diagnosis. The approval is based on evidence that the treatment slows the loss of insulin-producing cells.
The approval to treat children as young as 1 year old marks the first time a drug can delay type 1 diabetes progression in this youngest age group. The expansion addresses a critical gap in care for children at highest risk of rapid disease progression.
Researchers gathered at ATTD 2026 in Barcelona highlighted major growth in T1D screening initiatives worldwide. Early detection of the condition is becoming a central focus for the research community.
Vertex Pharmaceuticals announced changes to its stem cell therapy trials for Type 1 diabetes in April 2025. While one candidate was discontinued, another continues toward potential regulatory review.
Sanofi's Tzield has been accepted into an FDA expedited review program for people with stage 3 T1D, potentially cutting review time from over a year to just a few months. The move signals FDA recognition of significant unmet medical need in the T1D community.
Recent research demonstrates that engineered stem cells and cell-derived therapies can reverse new-onset type 1 diabetes in mouse models by calming the overactive immune system. These early findings move beyond insulin management toward addressing the root cause of the disease.
Researchers are developing cell-based therapies that use stem cells to create insulin-producing cells, potentially reducing or eliminating the need for insulin injections. Early clinical trials show promise, but significant challenges remain before these treatments become widely available.
Vertex presents data from Phase I/II stage of trial for type 1 diabetes Clinical Trials Arena
Sana Biotechnology's research shows that gene-modified pancreatic cells remain functional and continue making insulin over time. The findings represent progress in exploring whether edited cells could one day help people with Type 1 diabetes.
Pancreas transplantation offers real benefits for people with Type 1 diabetes, but keeping grafts healthy requires better ways to detect problems early. New molecular tools are changing how doctors monitor transplanted pancreases.
From inhaled insulin to medications that reduce carb counting, researchers are developing new options to make daily diabetes management easier. Here's what the science shows so far.
A new international position statement outlines when delivering insulin directly into the abdomen may help people with Type 1 diabetes achieve better blood sugar control and fewer dangerous low blood sugar episodes.
A clinical trial is evaluating whether implanting insulin-producing cells under the skin could help people with Type 1 diabetes manage their condition. Here's what the early research shows.
Researchers at Harvard are exploring stem cell therapy as a potential new treatment approach for Type 1 diabetes. While early-stage research shows promise, it's important to understand what scientists have actually discovered so far.
A clinical trial called Forward is testing whether stem cells engineered in the laboratory to produce insulin might reduce or eliminate the need for insulin injections in people with Type 1 diabetes. Early results suggest the approach warrants further study, though much research remains.
Researchers developed a thin, multilayered protective coating for pancreatic islet transplants that may help the immune system tolerate the transplanted cells. Early results in mice suggest the coating could improve transplant survival and restore blood sugar control.
Researchers are exploring stem cell transplants and immunotherapy as potential approaches to help people with Type 1 diabetes. Here's what's being studied and why this work matters.
Beta cell regeneration is a question many people with Type 1 diabetes wonder about. Here's what we know about where this research stands today.
A mother shares her 8-year-old son's journey with an experimental stem cell treatment and the changes she observed in his insulin needs and daily life. This is one family's story—not a clinical study.
A newly FDA-approved injectable drug called teplizumab may slow the progression to symptomatic Type 1 diabetes for people in early stages of the disease. Here's what the approval means for patients and families.
Dr. Nicole Sheenan from Cincinnati Children's Hospital shares insights on new advances in identifying and preventing type 1 diabetes in children.
Researchers are moving toward a new framework for Type 1 diabetes care that combines early detection, targeted prevention, and personalized therapies. Advanced biomaterials and cell transplantation technologies are making this vision closer to reality.
After the FDA approved teplizumab in 2022, doctors began ordering more comprehensive autoantibody tests to better identify who might benefit from the drug. A new study shows how one treatment option is reshaping how we screen for Type 1 diabetes risk.
As cell therapies for type 1 diabetes move closer to approval, Canadian experts are working to overcome regulatory and delivery challenges that could affect patient access.
Two Phase 3 trials are now underway to evaluate whether baricitinib, a drug that modulates immune signaling, can help preserve beta cell function early in Type 1 diabetes. Results could offer a new approach to managing blood sugar in newly diagnosed individuals.
A Swedish research team has successfully transplanted genetically modified insulin-producing cells into a person with type 1 diabetes, marking a significant milestone in regenerative medicine. The breakthrough sidesteps the need for immunosuppressant medications that have been required in previous transplant approache…
The immunotherapy drug teplizumab has been approved to slow insulin loss in children ages 8–17 with newly diagnosed type 1 diabetes. The approval expands the drug's use beyond its original stage 2 indication.
New data from the Phase 1/2 FORWARD trial shows that zimislecel, made from stem cell-derived insulin-producing cells, helped participants with Type 1 diabetes achieve excellent blood sugar control. Most participants no longer needed insulin injections after receiving a single infusion.
Imogen was identified as having early-stage type 1 diabetes through a research study, then became only the second child in the UK to receive teplizumab—a drug designed to delay the onset of the condition. Her mother shares what this opportunity has meant for their family.
Researchers are exploring whether engineered stem cells that reduce inflammation might create a safer environment for insulin-producing cells to survive. This preclinical strategy takes a different approach than directly replacing damaged beta cells.
Researchers discovered that inflamed ductal cells release tiny vesicles that increase a marker on beta cells' surfaces, potentially making them more recognizable to the immune system. This finding offers a new window into how Type 1 diabetes progresses at the cellular level.
A two-week intravenous treatment helped delay the progression of type 1 diabetes in people ages 8–49 who had stage 2 disease. This is one step in a longer journey toward better ways to manage the condition's progression.
JDRF is strategically funding clinical trials and new research projects to develop therapies that can slow or prevent Type 1 diabetes. Here's how the research pipeline works to move the field forward.
At a 2023 JDRF symposium, researchers, clinicians, and people living with Type 1 diabetes shared why intercepting and delaying the disease could transform millions of lives. Here's what that vision means in practice.
A panel of international researchers convened to explore what prevention and remission might mean for people at risk of or living with Type 1 diabetes. The discussion highlighted the evolving landscape of T1D research.
A major Type 1 diabetes screening initiative is shifting toward at-home testing methods and expanding who can participate. Here's what researchers are learning about making early detection more accessible.
From early detection through autoantibody screening to innovative device technology and immunomodulatory treatments, the landscape of pediatric Type 1 diabetes management is evolving. Here's what's happening in research and clinical practice.
The FDA has approved teplizumab as the first disease-modifying therapy shown to delay the onset of stage 3 type 1 diabetes in children and adolescents. Here's what the evidence shows and what it means for families.
A new study reveals that patients are willing to tolerate potential side effects if novel therapies offer meaningful improvements to their diabetes management. The finding highlights an important shift in how people think about treatment trade-offs.
A quarter-century into cell transplantation for Type 1 diabetes, researchers are learning how to overcome early limitations and move closer to sustained remission. Here's where the science stands.
Researchers are exploring immunotherapy and stem cell approaches to address the root causes of Type 1 diabetes. Here's what early research suggests about these emerging strategies.
Researchers are exploring islet transplantation as a way to restore insulin-producing function in people with Type 1 diabetes. Understanding how this approach works—and its current limitations—can help patients and families evaluate emerging options.
City of Hope is enrolling adults recently diagnosed with Type 1 diabetes in a study exploring whether denosumab, an FDA-approved osteoporosis medication, might help preserve remaining beta cell function.
Researchers and companies developing next-generation islet cell treatments face rigorous regulatory and manufacturing hurdles. A new guide outlines what it takes to bring these complex therapies from laboratory to patient.
For a century, insulin has been the backbone of Type 1 diabetes management—but it has real limitations. A new research initiative called ATIC is exploring immunotherapy approaches that could address the disease at its source.
A new study shows that access to a disease-modifying therapy has shifted how and who gets tested for islet autoantibodies—the early warning signs of Type 1 diabetes. But important gaps remain.
Researchers are working on transplanting insulin-producing cells into people with Type 1 diabetes. A major challenge has been protecting these new cells from the immune system. Recent work suggests progress on this problem—but we're still in early stages.
Researchers are exploring ways to modify stem cells so the immune system won't attack transplanted insulin-producing cells, potentially reducing the need for immune-suppressing drugs in future Type 1 diabetes treatments.
Researchers are testing tegoprubart, a medication that may help reduce the burden of immunosuppressive drugs needed after islet cell transplantation. Early results suggest potential for making this minimally invasive procedure safer and more accessible.
Scientists are exploring how extracellular vesicles—microscopic particles released by cells—might offer new ways to spot beta cell damage and track disease progression in Type 1 diabetes.
Researchers are studying pancreatic tissue from people with Type 1 diabetes to understand what happens inside the organ during the disease. These insights are fueling new approaches to preserve insulin production and potentially reverse the condition.
Multiple research groups are exploring stem cell transplants as a potential functional cure for Type 1 diabetes. While progress is genuine, experts emphasize the importance of realistic expectations about when these therapies might become available.
Before any new Type 1 diabetes treatment reaches patients, it must pass through years of research and rigorous testing. Here's how the drug development and approval process actually works.
City of Hope is recruiting newly diagnosed adults for a study testing whether denusumab, an FDA-approved osteoporosis medication, might help protect and regenerate insulin-producing cells in early Type 1 diabetes.
Researchers are evaluating whether implanting islet cells—the insulin-producing tissue from the pancreas—into the forearm could help people with Type 1 diabetes manage their blood sugar. The work is in very early stages.
New research from Vertex suggests that transplanted insulin-producing cells can restore blood sugar control in some people with Type 1 diabetes, though the approach currently requires immunosuppressant drugs.
Vertex Pharmaceuticals is developing a therapy that replaces insulin-producing cells, with early results showing promise for people with severe hypoglycemia. Here's what the evidence shows so far.
Researchers have reported success in a single patient who received cells reprogrammed to produce insulin, reducing her need for insulin injections. Here's what the early report shows—and what remains unknown.
A company is testing genetically modified insulin-producing cells designed to evade the immune system, with early results showing one patient producing insulin without requiring immunosuppressive drugs.
Vertex Pharmaceuticals reported that 10 of 12 study participants became insulin-independent for at least one year using transplanted cells made in the laboratory. All participants required ongoing immunosuppression medication to prevent rejection.
A major obstacle prevents transplanted insulin-producing cells from surviving in the body. Researchers are now developing ways to protect these grafts from immediate immune attack.
Scientists are working to create artificial pancreatic tissue that could one day replace damaged insulin-producing cells without the need for donor organs or lifelong immunosuppression. A new review examines where this technology stands and what challenges remain.
Researchers have developed a method to coax bone marrow stem cells into forming structures that resemble pancreatic islets, offering a potential new source for transplant research and drug testing.
New research suggests that a smaller dose of an inexpensive, long-used immunosuppressant drug can slow the loss of insulin-producing cells in newly diagnosed Type 1 diabetes. The findings could offer a lower-cost option with fewer side effects than previous approaches.
Breakthrough T1D researchers have published guidelines to help accelerate the development and availability of cell replacement therapies that could offer new treatment options for people with Type 1 diabetes.
Scientists are exploring stem cell therapy, immunotherapy, and bioengineering as potential paths to replace insulin-producing cells lost to autoimmunity. These approaches remain in development, but researchers are making progress on long-standing technical and safety challenges.
Vertex Pharmaceuticals is developing a manufactured islet cell therapy designed to replace the insulin-producing cells that the immune system destroys in Type 1 diabetes. We spoke with the researchers leading this work to understand how it works and what comes next.
New research suggests that a low dose of an inexpensive, decades-old immune-suppressing medication can delay the progression of type 1 diabetes when given shortly after diagnosis. The drug appears effective with fewer side effects than higher doses used in previous studies.
A new encapsulation platform aims to shield pancreatic islet cell transplants from immune attack, potentially reducing the need for immunosuppressant drugs. Researchers at Rice University have received a two-year grant to refine and test the approach.
Researchers studying a rat model of Type 1 diabetes are uncovering how the pancreas's local environment influences disease progression. These findings could help scientists design better transplant strategies and understand why the condition develops.
Researchers are testing whether a natural sugar molecule used by cancer cells to hide from the immune system could one day help protect the beta cells destroyed in type 1 diabetes.
A continent-wide project called EDENT1FI is testing hundreds of thousands of children for type 1 diabetes before symptoms appear, aiming to intervene early and improve outcomes.
LyGenesis has received funding to explore whether training the thymus—a key immune organ—could allow pancreatic islet transplants to work long-term in people with Type 1 diabetes without rejection.
Researchers found that a substance derived from platelets can help stem cell-derived beta cell grafts survive longer in the body by reducing immune cell infiltration. The findings suggest a potential way to improve stem cell transplant therapies for Type 1 diabetes.
Breakthrough T1D Canada is calling for $62 million in government funding over five years to create a national network that could accelerate cell and gene therapies toward patients. The investment would position Canada to lead in regenerative medicine research and attract global clinical trials.
Sanofi's teplizumab has become the first monoclonal antibody approved in the UK for early-stage type 1 diabetes, offering eligible patients a way to delay disease progression by approximately three years.
A new study of Spanish adults with Type 1 diabetes finds that people with stronger cooking knowledge and healthier cooking habits tend to have better blood sugar control. The research suggests that teaching practical cooking skills could be a valuable part of diabetes education.
The FDA has approved teplizumab, marking the first medication shown to delay the development of type 1 diabetes in people at high risk. This approval represents a significant milestone in diabetes prevention, though the drug delays rather than prevents the disease.
A new partnership aims to advance cell-based approaches to treating Type 1 diabetes. The collaboration brings together a biotech company and one of the nation's leading medical centers.
Eledon Pharmaceuticals presented updated findings from an investigator-initiated trial testing tegoprubart in patients with Type 1 diabetes who received islet cell transplants. The data was shared at the 2026 American Diabetes Association Scientific Sessions.
Scientists at Joslin Diabetes Center are collaborating on a multi-pronged approach to understand and potentially reset the immune system in Type 1 diabetes. The work focuses on how T cells develop and why they mistakenly attack insulin-producing cells.
Early clinical trial results from Vertex Pharmaceuticals suggest that replacing damaged insulin-producing cells with healthy transplanted ones may help people with Type 1 diabetes reduce or stop insulin injections.
Scientists are using CRISPR gene editing to create insulin-producing cells from mesenchymal stromal cells that might better evade immune rejection in Type 1 diabetes patients. This approach aims to overcome one of the biggest obstacles to cell-based diabetes treatments.
Researchers have successfully converted cells in the gastrointestinal tract into insulin-producing cells in laboratory and animal studies. This discovery could one day lead to a renewable source of replacement cells for people with Type 1 diabetes.
A new study finds that cooking competency—the ability to prepare meals from scratch and understand nutrition labels—is linked to eating fewer ultra-processed foods in people with Type 1 diabetes.
Scientists discovered that pancreatic ductal cells can activate the immune system when exposed to inflammatory signals, offering new insights into how Type 1 diabetes develops. This finding may help researchers understand disease progression and explore new prevention approaches.
Researchers developed an injectable material that delivers oxygen and growth factors to transplanted insulin-producing cells, addressing a major barrier to islet transplant success in mice. The approach showed promise in early testing but remains far from clinical use.
Researchers are testing a staining technique that makes transplanted islets visible under a microscope, which could improve how doctors monitor whether transplants are working in patients with Type 1 diabetes.
Mount Sinai's Obesity, Diabetes and Metabolism Institute is pursuing research into therapies that could help regenerate insulin-producing beta cells. Here's what the institute's leadership is working toward.
Researchers are testing a procedure that transplants insulin-producing cells into the liver, with some patients reducing or stopping insulin injections. Early results are encouraging, but significant hurdles remain.
A participant in an early-stage trial at the University of Chicago received transplanted pancreatic islet cells combined with an immune-protecting drug. We look at what the experience reveals about a potential future treatment approach.
Research in mice suggests that pairing an immune-modulating antibody with a compound that supports beta cell health may offer stronger protection against Type 1 diabetes than either treatment alone.
Two new studies presented at a major diabetes conference show that stem cell-derived insulin-producing cells can restore insulin production in people with Type 1 diabetes. While results are encouraging, researchers emphasize these are still early-stage treatments requiring immunosuppressive medications.
Researchers have shortened the time needed to grow insulin-secreting islet cells from 40 days to 14 days using a new stem-cell approach. The faster production method aims to reduce safety risks associated with cell transplantation for type 1 diabetes.
The FDA has expanded approval of Tzield to stage 3 type 1 diabetes, making it the first disease-modifying therapy available to children and teens shortly after diagnosis. The drug works by preserving the body's insulin-producing cells.
Researchers at Hebrew University have won a prestigious European grant to investigate an unexplored theory about how type 1 diabetes begins—focusing on problems within insulin-producing cells rather than viral triggers.
The FDA has approved Tzield for children as young as one year old to help delay the progression to insulin-dependent Type 1 diabetes. This expansion makes the disease-modifying therapy available to a younger population at high risk of rapid disease progression.
A small trial at University of Chicago Medicine tested tegoprubart, an experimental antibody designed to prevent rejection of transplanted insulin-producing cells without using traditional immunosuppressive drugs. Early results suggest the approach may help patients achieve insulin independence.
University of Florida scientists have identified how the immune system begins its assault on insulin-producing cells, offering new insight into the earliest stages of Type 1 diabetes development.
The Australasian Type 1 Diabetes Immunotherapy Collaborative held its first town hall to discuss immunotherapy research and clinical trials. Here's what you need to know about this new community initiative.
Breakthrough T1D highlights major presentations from the American Diabetes Association's annual scientific meeting. Here's what researchers shared about the latest Type 1 diabetes advances.
New research confirms that teplizumab helps preserve insulin-producing cells in people with stage 2 type 1 diabetes, delaying the progression to stage 3. The medication works by reducing the body's attack on these critical cells.
A detailed case study shows that type 1 diabetes developing after haploidentical stem cell transplantation may sometimes arise from a patient's own residual immune cells rather than from donor cells—a finding that could reshape how doctors understand and prevent post-transplant diabetes.
Immunotherapies represent a fundamentally new approach to Type 1 diabetes by targeting the immune attack on insulin-producing cells rather than just managing blood sugar. Recent advances highlight how scientists are working to slow or stop the destruction that drives the disease.
Researchers are working to grow insulin-producing cells from stem cells to replace those damaged by Type 1 diabetes. While the science is advancing, significant hurdles remain before this approach reaches patients.
Two very different autoimmune diseases share surprising similarities in how they attack the body. Researchers are using that overlap to develop better targeted therapies for both conditions.
Scientists are learning that the energy factories inside cells play a crucial role in developing insulin-producing cells from stem cells. Understanding this process could improve transplant therapies for Type 1 diabetes.
Scientists at Mount Sinai have identified a new class of drugs that appear capable of prompting human pancreatic beta cells to regenerate. The work represents a shift in thinking about whether beta cell renewal is possible in diabetes.
A podcast discussion features a woman with Type 1 diabetes who has reduced her daily insulin to just a few units after 13 years of dependence. We explore what her story tells us and what questions remain.
A new encapsulated cell replacement therapy being tested in Canada uses a protective pouch to keep donor insulin-producing cells alive and functional. Early safety results suggest the approach may be viable.
Greenstone Biosciences received funding to develop a patient-derived platform that mimics the insulin-producing cells attacked in Type 1 diabetes, potentially unlocking insights into why the disease affects people differently.
New research shows that insulin-producing cells grown from stem cells can regulate blood glucose at human levels when transplanted into mice. The findings offer insight into what characteristics may be needed for these implants to work as a potential diabetes treatment.
A new immunotherapy drug has been approved for NHS use that can delay the onset of Type 1 diabetes by approximately three years. Here's what patients and families need to know.
Researchers are pursuing strategies that combine cell replacement with immune tolerance—moving away from lifelong immunosuppression toward treatments that could offer functional recovery. Here's what the latest science shows.
Patti Columbe has managed Type 1 diabetes with every available tool—pumps, CGMs, and even a diabetic alert dog. Now she's participating in a pivotal clinical trial testing manufactured islets, a potential step toward reducing the burden of daily diabetes management.
Bipartisan legislation renews the Special Diabetes Program, ensuring continued federal investment in type 1 diabetes research. The program has contributed nearly $3.6 billion to advancing treatments and improving outcomes for the T1D community.
As the organization formerly known as JDRF launches its inaugural Clinical & Research Congress, its leadership outlines priorities spanning early detection, emerging therapies, and beta cell research.
Researchers gathering in New Orleans highlighted both promise and challenges in developing cell-based treatments for Type 1 diabetes. A key focus: making clinical trials more accessible to patients who could benefit.
Researchers are developing techniques to help transplanted insulin-producing cells thrive in the body without requiring long-term immune suppression. Recent work focuses on creating better environments for these cells and making them invisible to the immune system.
The first disease-modifying therapy for stage 3 type 1 diabetes has received FDA accelerated approval. Tzield is designed to slow the decline of insulin production in recently diagnosed children ages 8–17.
Researchers are developing treatments that target the immune system to delay or modify how Type 1 diabetes develops. These emerging approaches offer hope for people at risk or newly diagnosed.
Breakthrough T1D has awarded funding to support a clinical trial investigating whether SAB-142 can help preserve remaining insulin production in people with newly diagnosed Type 1 diabetes.
New data from a major diabetes conference and a comprehensive review of immunotherapy studies show that teplizumab can slow the progression of Type 1 diabetes in newly diagnosed people. Here's what the evidence actually demonstrates.
A new study from Vertex shows that lab-grown insulin-producing cells helped 10 out of 12 patients achieve insulin independence. The advancement offers hope, but important questions about long-term safety remain.
Researchers have developed a new approach to islet transplantation that combines insulin-producing cells with blood vessel cells in a supportive scaffold, showing promise in early animal studies for restoring normal blood sugar control.
Researchers found that adding a specific type of immune cell during the development of lab-grown insulin-producing cells makes them mature faster and work more effectively when transplanted into diabetic mice.
Scientists used advanced imaging to study what happens when stem cell-made insulin-producing cells are transplanted into the body. The findings show important differences between using a person's own cells versus donor cells.
Researchers developed a specialized nanofibrous scaffold that helps insulin-producing islet cells survive and function when transplanted under the skin. The approach worked well in mice and may one day offer a less invasive way to treat Type 1 diabetes.
A new study reveals how patients and scientists view islet transplantation differently, highlighting the importance of listening to both perspectives as this potential therapy advances.
Researchers found that people at risk for Type 1 diabetes who moved into a normal weight range had about half the risk of progressing to clinical disease. The finding offers a new perspective on factors that may influence how quickly autoimmune Type 1 diabetes develops.
Researchers developed a retrievable hydrogel device designed to protect transplanted insulin-producing islet cells from the immune system and oxygen shortages—two major barriers to cell therapy success. Early animal studies show the approach may allow islets to function without lifelong immunosuppressant drugs.
Islet cell transplants are showing promise in helping some adults with type 1 diabetes reduce or stop insulin injections. Here's what the science shows—and what challenges remain.
An EU-funded research team has developed a retrievable implant designed to restore the body's natural ability to regulate blood sugar. The device could offer an alternative to current treatments, though significant development work remains.
A landmark study published in The Lancet Diabetes & Endocrinology demonstrates that screening children for type 1 diabetes autoantibodies is effective and could prevent thousands of emergency diagnoses. Early detection opens the door to new immunotherapy treatments and better health outcomes.
Eli Lilly announced phase 3 clinical trials for baricitinib, a JAK inhibitor that showed promise in earlier research for preserving insulin-producing cells in newly diagnosed type 1 diabetes.
A man with type 1 diabetes received transplanted insulin-producing cells that were genetically modified to evade immune rejection, eliminating the need for immunosuppressive drugs. Early results show the approach is feasible, though longer follow-up is needed to understand its safety and durability.
The biotech company plans to test CNTY-813, a lab-grown cell therapy, in human patients starting in 2027. The funding reflects investor confidence in a new approach to Type 1 diabetes treatment.
New research shows that using small RNA molecules to reduce apolipoprotein CIII—a protein elevated in Type 1 diabetes—preserved insulin-producing cells and delayed disease onset in animal models. The findings suggest a potential therapeutic approach during the critical prediabetic window.
Researchers at TrialNet and elsewhere are studying ways to prevent or delay Type 1 diabetes onset. Dr. Michael Haller discusses how these prevention studies are progressing and what they might mean for newly diagnosed patients.
Researchers are working to understand and identify warning signs for a rare form of type 1 diabetes that can develop in cancer patients receiving immune checkpoint inhibitor treatment.
Researchers reviewed years of published studies on porcine islet xenotransplantation for Type 1 diabetes and found a surprising gap: there's almost no guidance on how to properly inform patients before they participate in these experimental procedures.
Vertex Pharmaceuticals has announced changes to its Type 1 diabetes programs. Here's what the update means for the research landscape.
New studies tracking people who received teplizumab reveal how the treatment performs outside clinical trials and what patients and caregivers actually experience.
A private placement funding round will help support NewcelX Ltd.'s work on a Type 1 diabetes program. The company is among many organizations exploring new approaches to the disease.
A pediatric center in Canada has achieved a first-time milestone in type 1 diabetes treatment. Learn what this advancement means for young patients and families.
Researchers have successfully transplanted 80 million engineered cells into a patient with type 1 diabetes in a procedure that did not trigger immune rejection. This marks a significant milestone in cell therapy research for diabetes.
Islet xenotransplantation—using animal cells to replace insulin-producing tissue—shows promise as an alternative to lifelong insulin therapy. But scientists and ethicists are working to address significant questions about animal welfare, consent, and fairness.
A new study reveals the behind-the-scenes research that helped bring teplizumab to approval. Understanding how scientists overcame testing challenges offers insight into how immunotherapies are developed.
Researchers are investigating whether neighboring pancreas cells can be converted into insulin-producing beta cells using a simple peptide injection—a potential path toward restoring natural insulin production in Type 1 diabetes.
A parent shares how their child's mood and emotional well-being changed after receiving stem cell treatment for Type 1 diabetes. While personal stories offer hope, they reflect individual experiences rather than proven outcomes.
A participant in the EladON trial shares her story of receiving an islet cell transplant alongside Teplizumab treatment. We look at what her experience reveals about this emerging approach.
Islet transplantation represents an evolving approach to type 1 diabetes management. Here's what you need to know about how this research is developing.
A small trial is testing whether transplanted insulin-producing cells, protected by a new drug approach, can reduce or eliminate the need for insulin injections in people with Type 1 diabetes.
Researchers are making new discoveries about how pancreatic beta cells work and why they're destroyed in type 1 diabetes. These insights could lead to better treatments in the future.
The approval marks the first disease-modifying treatment option for people diagnosed with stage 3 Type 1 diabetes. Tzield can now be used in children and teenagers ages 8-17 within eight weeks of diagnosis.
A single infusion of zimislecel, an investigational cell-based treatment, helped restore insulin production in patients with severe low blood sugar events in early trial results.
Researchers have developed a new type of insulin-secreting organoid grown from gastric tissue that naturally resists immune attack and can be further engineered to evade destruction. This advance could make cell transplants for Type 1 diabetes more viable.
The FDA has approved Tzield for use in people with stage 3 Type 1 diabetes. Here's what the approval represents and why it matters to the community.
Researchers are developing ways to grow insulin-producing cells in the laboratory and transplant them back into people with Type 1 diabetes. Here's what the science shows so far—and what questions remain.
A Canadian research team is investigating ways to help transplanted insulin-producing cells survive longer in the body. Here's what they're working on and why it matters.
Researchers have discovered that a small population of T cells marked by two specific proteins—LEF1 and TCF1—sustain the autoimmune attack in type 1 diabetes. Understanding these stem-like immune cells could point toward new ways to stop the disease before it takes hold.
A YouTube video documents one person's blood sugar experience after a pig islet cell transplant. Here's what we know—and what we need before drawing any conclusions.
A new study published in the New England Journal of Medicine shows that stem cell therapy helped 10 of 12 patients reduce or stop needing insulin injections. While promising, researchers emphasize this is early-stage work with important limitations.
A new cell therapy approach combining blood-forming stem cells with pancreatic islet cells stopped autoimmune attacks and reversed diabetes in mice, offering a potential pathway toward human trials.
University of Wisconsin–Madison scientists found that removing a stress-response gene in insulin-producing cells protected mice from developing Type 1 diabetes, suggesting a new approach beyond immune suppression.
A biotechnology company developing stem cell-derived insulin-producing cells plans to share preclinical research at two major scientific conferences this fall. The work focuses on manufacturing challenges for potential off-the-shelf cell therapies.
GentiBio has dosed the first participant in POLARIS, a Phase 1 clinical trial testing GNTI-122, an engineered regulatory T cell therapy designed to preserve the body's natural insulin production in people recently diagnosed with Type 1 diabetes.
A new approach using endoderm stem cells to create pancreatic islet tissue has been tested in three patients with type 1 diabetes. The method is faster and may be safer than traditional stem cell approaches.
A Phase 1 trial of NNC0361-0041, an experimental plasmid-DNA immunotherapy developed by Novo Nordisk and TrialNet, has completed enrollment and demonstrated early safety findings in adults. The results represent an important first step toward understanding how this immune-targeting approach might work in type 1 diabet…
A participant in the Eledon trial has reduced her daily insulin requirement to just a few units—a significant change that highlights ongoing research into slowing or halting Type 1 diabetes progression. We spoke with her about her experience.
Scientists are exploring whether the insulin-producing beta cells damaged in Type 1 diabetes can be regenerated. Here's what the current research landscape looks like and why this question matters.
Scientists at Joslin Diabetes Center are exploring a coordinated approach to Type 1 diabetes that targets the immune system malfunction and beta cell loss simultaneously. The strategy rests on three key steps: reset, regulate, and regenerate.
Two biotech companies announced a collaboration to launch clinical trials of a gene-edited cell replacement approach. Here's what this partnership means for the Type 1 diabetes community.
The Australasian Type 1 Diabetes Immunotherapy Collaborative held its first town hall to connect patients, families, and clinicians around emerging immunotherapy approaches. The event highlighted the growing focus on immune-based treatments in the region.
Researchers are investigating whether multipotent stromal cells—immune cells from bone marrow—can trigger beta cell regeneration and reduce blood sugar levels in Type 1 diabetes. Early evidence from animal studies and early clinical trials is encouraging, though many questions remain.
A new partnership brings together researchers at UMass, Harvard, and Jackson Laboratory to study how the immune system destroys insulin-producing cells—and how to replace them.
Scientists are exploring ways to help the body's insulin-producing cells multiply. Here's what early work in this area tells us.
Oliver Zilinskas was 10 years old when subtle symptoms—fatigue, thirst, weight loss—came together to reveal a Type 1 diabetes diagnosis. His family's story shows why recognizing these warning signs matters.
A clinical trial compared a newer drug combination to the standard approach for people receiving islet transplants for Type 1 diabetes. Early results suggest the new combination may offer benefits, including better kidney protection.
Researchers at the University of Chicago are presenting updated results from a trial of tegoprubart, a drug designed to help islet transplants survive and function in people with Type 1 diabetes. The findings will be shared at the American Diabetes Association's annual scientific conference.
Researchers at the University of Queensland have started a clinical trial of a new drug that aims to rebalance the immune system in people recently diagnosed with Type 1 diabetes. The approach, tested successfully in mice, combines a pancreatic protein with vitamin D to calm immune attacks on insulin-producing cells.
The expanded approval allows children as young as 1 year old to receive teplizumab, an immunotherapy that can delay the progression of Type 1 diabetes. This marks the first opportunity for very young children at high risk to potentially postpone symptom onset.
NewcelX and Eledon Pharmaceuticals have partnered to evaluate whether pairing a stem cell-derived insulin-producing cell therapy with an immune-dampening antibody could offer a more durable treatment approach for type 1 diabetes.
Eli Lilly is launching phase 3 trials of baricitinib, a pill already approved for rheumatoid arthritis, to investigate whether it can delay the onset of type 1 diabetes.
Sana Biotechnology reports a significant milestone in cell therapy: transplanted insulin-producing islet cells that were engineered to evade the immune system survived for over a year in a Type 1 diabetes patient without immunosuppressive drugs.
A comprehensive review of 30 years of stem cell research shows two main approaches gaining ground: replacing damaged beta cells and calming the immune system. Here's where the field stands today.
Multiple therapies in development are advancing toward the goal of reducing or eliminating insulin dependence for people with Type 1 diabetes. Researchers describe the current state of the pipeline as making 'remarkable progress.'
A new drug offers the first approach to actually slow the progression of Type 1 diabetes rather than just manage it. Here's what you need to know about this milestone treatment.
Scientists are learning more about what happens inside the pancreas of people with Type 1 diabetes by studying donated tissue samples. This research could help advance future treatments.
A new JDRF Center of Excellence brings together researchers from UMass Chan Medical School, Harvard, and Jackson Laboratory to study how Type 1 diabetes develops—work that could eventually lead to better treatments.
Researchers are studying a special strain of mice that naturally develops Type 1 diabetes to understand how the immune system attacks insulin-producing cells. These insights are helping guide the development of new immunotherapies that could one day prevent or slow disease onset in people.
Recent breakthroughs in immunotherapy and gene editing offer hope for delaying Type 1 diabetes and preserving insulin-producing cells—moving medicine beyond insulin management toward addressing what causes the disease.
Two leading companies announced a clinical trial partnership to test a novel approach: using CRISPR gene editing to create replacement cells for Type 1 diabetes treatment. Here's what we know about this early-stage research.
A new study reveals that young adults with Type 1 diabetes experience significant burden from their care routines and report moderate quality of life. The findings highlight where support is needed most.
New research reveals that CD8 T cells attacking the pancreas in Type 1 diabetes have a specific, recognizable trait: they react directly to beta cells. This discovery could help researchers develop better ways to monitor and target the immune cells driving the disease.
Scientists are making meaningful strides in growing insulin-producing cells from stem cells to treat Type 1 diabetes, but significant challenges remain before this approach becomes a practical therapy.
As islet cell therapies advance through development, medical centers worldwide are training to deliver these insulin-producing cell treatments to patients with Type 1 diabetes. A global network of expert centers is working to ensure the healthcare system will be ready when these therapies reach patients.
A pharmaceutical company has started recruiting patients for a Phase 2 study of an experimental medicine designed to address insulin resistance and mitochondrial function in people with Type 1 diabetes. The trial will test whether the drug can improve blood sugar control in adults using automated insulin delivery syst…
Scientists have developed a faster method to grow insulin-secreting islet cells from stem cells, reducing production time from 40 days to 14 days. The approach aims to make regenerative islet transplants safer and more practical for people with type 1 diabetes.
Australia's therapeutic regulator has approved Tzield (teplizumab), marking the first treatment designed to delay the clinical onset of type 1 diabetes. The approval opens new options for people identified in the early stages of the condition.
Mayo Clinic has announced a collaboration with Sana Bio focused on developing cell-based therapies for Type 1 diabetes. The partnership includes a financial investment from Mayo Clinic in the biotech company.
Researchers are investigating new approaches to help insulin-producing cells survive and function better after transplantation, a key step toward making cell-based treatments more effective for people with Type 1 diabetes.
The company has been selected to share preclinical data on CNTY-813, an experimental Type 1 diabetes treatment, at two significant 2026 conferences focused on diabetes research and care.
Researchers are launching a new clinical trial to evaluate whether specially engineered immune cells can help preserve insulin production in people with type 1 diabetes. The approach represents an experimental strategy distinct from existing approved therapies.
Researchers have identified a unique subset of pancreatic beta cells that persist in people with established Type 1 diabetes, offering clues about how some cells escape immune attack. Understanding these surviving cells could point toward new strategies for prevention and disease reversal.
Promising research is happening on multiple fronts, yet people managing Type 1 diabetes today still face daily management challenges. Understanding how to hold hope and present reality together matters.
Scientists have pinpointed a key culprit behind the autoimmune attack in type 1 diabetes and are developing strategies to interfere with it. The work could eventually lead to therapies that delay or prevent the disease.
A first-in-human study demonstrates that engineered pancreatic cells can survive and produce insulin in a Type 1 diabetes patient without requiring immune-suppressing medications. Researchers are investigating whether this approach could offer a new path toward cell-based therapies.
A 12-patient trial at the University of Chicago tested a new immunosuppression approach alongside islet transplantation. Most participants achieved insulin independence and improved blood sugar control.
Rep. Kim Schrier, MD, the only current member of Congress living with Type 1 diabetes, highlighted the importance of sustained federal support for T1D research at a recent advocacy conference.
LADA, or latent autoimmune diabetes in adults, is a rare form of Type 1 diabetes that develops slowly and often goes misdiagnosed. Understanding its features can help people get the right treatment.
NewcelX has appointed Dr. Camillo Ricordi, a pioneering figure in diabetes research, to help guide the development of new Type 1 diabetes therapies.
The organization formerly known as JDRF is pursuing cure research alongside practical improvements to daily diabetes management. Here's how they're working across multiple fronts to transform the field.
A University of Chicago study combined islet cell transplantation with teplizumab to help one person discontinue insulin therapy. Here's what her case reveals about where Type 1 treatment research stands.
A newly approved monoclonal antibody can delay when Type 1 diabetes develops in people at high risk. It buys time without insulin—but it is not a cure.
Researchers at a diabetes center are exploring a combined strategy to address why single-approach clinical trials have had limited long-term success. The collaboration examines how combining multiple immune-targeting methods might offer more sustained benefit.
A participant in a University of Chicago study combined transplanted islet cells with the drug teplizumab and achieved insulin independence. Her experience offers a real-world look at what's involved in this experimental approach.
For people who receive a pancreas transplant to treat Type 1 diabetes and kidney disease, the autoimmune condition can sometimes recur. Doctors now have better tools to tell the difference between a returning immune attack and transplant rejection.
New findings from an ongoing clinical trial show promise for zimislecel (VX-880), an investigational therapy designed to replace insulin-producing cells in people with Type 1 diabetes. The data were presented at the American Diabetes Association annual conference and published in the New England Journal of Medicine.
Counterfeit and compounded versions of weight-loss medications are causing serious harm. Here's what you need to know about safety risks and why FDA approval matters.
A landmark publication from Breakthrough T1D outlines how the field can accelerate beta cell replacement therapies to patients safely and equitably. The roadmap addresses clinical trial design, participant eligibility, and collaboration across the research ecosystem.
The ELEVATE study will compare Medtronic's new MiniMed NMX8 pump to today's automated insulin delivery systems in nearly 230 adults with type 1 diabetes. Results could show whether newer technology offers meaningful improvements in blood sugar management.
A new approach to islet cell transplantation combined with a targeted immunosuppressive drug has allowed six Type 1 diabetes patients to stop taking insulin. The trial is expanding to enroll more participants.
Researchers are exploring a novel strategy to treat Type 1 diabetes by retraining the immune system to stop attacking beta cells rather than replacing them. Imcyse, a Belgian biotech company, is developing immunotherapies designed to restore immune tolerance.
A viral video makes bold promises about Type 1 diabetes and CRISPR gene editing, but lacks the scientific evidence needed to inform our community.
Researchers are exploring ways to protect and strengthen the insulin-producing cells that often survive even years after a Type 1 diabetes diagnosis. Understanding what remains could open new treatment possibilities.
Teplizumab represents a shift in how we approach Type 1 diabetes by targeting the disease process itself rather than just managing blood sugar. Here's what this milestone means for the community.
Even as newer CF treatments improve lung function, cystic fibrosis related diabetes remains a growing challenge. Scientists are exploring genetic factors, nutrition, and stem cell research to better prevent and manage the condition.
The Chinese National Medical Products Administration has approved teplizumab (Tzield) for patients with stage 2 type 1 diabetes, marking the first disease-modifying therapy available in China for delaying progression to stage 3 disease.
A new annual report shows that stem cell-derived beta cell research is moving from nonprofit labs to commercial companies, signaling growing investment in cell replacement approaches for type 1 diabetes.
Researchers in Geneva have developed an experimental gel designed to protect insulin-producing cells after transplantation, addressing a major obstacle in cell replacement therapy for type 1 diabetes.
A regenerative medicine company has received FDA feedback supporting its plan to test a stem cell-derived therapy combined with an immunomodulatory drug. The approval to move forward represents an early but important step in clinical development.
Researchers are investigating ways to replace the insulin-producing beta cells that the immune system destroys in Type 1 diabetes. These approaches offer potential new treatment directions, though significant work remains ahead.
The FDA has granted accelerated approval to Tzield (teplizumab) based on stage 3 trial data, marking a significant milestone in efforts to delay Type 1 diabetes onset in at-risk individuals.
A participant in a clinical trial combining islet cell transplantation with Teplizumab shares what life has been like six months after the procedure, including what it means to live without insulin injections.
Researchers followed people with Type 1 diabetes who received islet cell transplants and found that while most maintained stable vision, rapid blood sugar improvement triggered temporary eye changes in some patients.
Researchers are documenting a rare but serious side effect: Type 1 diabetes developing in patients receiving immune checkpoint inhibitor therapy for cancer. Understanding this connection could help doctors identify at-risk patients earlier.
Researchers at Joslin Diabetes Center are pursuing an approach that tackles Type 1 diabetes from three angles at once: stopping immune attacks on beta cells, preventing them from restarting, and restoring the body's natural insulin-producing capacity.
Researchers, patients, and advocates share a common goal: finding better treatments and ultimately a cure for Type 1 diabetes. Progress depends on sustained effort and collaboration across the entire community.
Researchers developed an ultra-thin protective coating for islet cells that kept transplanted cells working in diabetic mice for over 100 days without triggering immune rejection.
A large Phase 3 study of Diamyd, an experimental therapy designed to preserve insulin production, did not meet its primary goal—but researchers say the results still offer valuable insights for future drug development.
New analysis shows that research funded by the Special Diabetes Program has generated substantial federal savings through innovations like continuous glucose monitors and automated insulin delivery systems. The program is now facing expiration and needs congressional renewal.
A new over-the-counter glucose monitor for young children and a disease-modifying therapy for newly diagnosed teens represent meaningful progress in how Type 1 diabetes can be monitored and managed.
The FDA-required confirmatory trial BETA-PRESERVE is now recruiting children and young adults ages 1–25 to verify whether teplizumab can help preserve insulin production after a type 1 diabetes diagnosis.
Researchers are testing whether a GLP-1 analogue can safely help young adults with type 1 diabetes manage weight while monitoring effects on heart health markers.
Recent breakthroughs in stem cell transplantation, beta-cell preservation, and regeneration are opening new possibilities for people with Type 1 diabetes. Here's what the latest research shows.
A major funding organization is backing continued research into SAB-142 beyond its first 100 days of treatment. Here's what we know about this next phase of investigation.
New data from Vertex's ongoing study reveals that 10 of 12 patients with Type 1 diabetes remained insulin-independent for a full year after receiving VX880 therapy. The results come with an important trade-off: all participants require immunosuppressive medications to maintain the benefit.
For the first time, a new class of drugs is offering a way to delay Type 1 diabetes onset—marking a significant shift in how the disease can be managed. Several clinical trials are now testing immunotherapies that could open the door to new prevention and treatment strategies.
A comprehensive review of five clinical trials shows teplizumab can preserve insulin-producing cells and reduce insulin needs in newly diagnosed Type 1 diabetes, though benefits decline over time.
Researchers and doctors have long discussed the possibility of breakthroughs for Type 1 diabetes—but what does the current research landscape actually show? Here's a breakdown of the science behind prevention and intervention studies, and what different research goals actually mean.
The FDA has broadened access to teplizumab (Tzield) for younger patients, now approving the treatment for children ages 8 and up who have been recently diagnosed with Type 1 diabetes. The expansion reflects growing evidence that the medication can delay disease progression in pediatric populations.
A viral video claims stem cells have cured Type 1 diabetes in individual patients. Here's what the evidence actually shows—and what questions remain.
Researchers at Breakthrough T1D have published guidelines designed to help move beta cell replacement therapies from the lab into clinical practice faster. The roadmap addresses how to design trials and navigate regulatory pathways for these cell-based treatments.
The Type 1 Diabetes Grand Challenge aims to accelerate research into restoring insulin production and stopping immune system damage. Because type 1 affects everyone differently, researchers are exploring multiple pathways rather than seeking a single cure for all.
Continuity Biosciences and Breakthrough T1D are collaborating to test NICHE, an implantable device designed to protect insulin-producing cells from immune attack while minimizing whole-body immunosuppression. The technology aims to address two major barriers that have limited islet transplantation success.
Breakthrough T1D is expanding a research center across two universities to develop and test new therapies targeting two serious complications that affect many people with Type 1 diabetes.
Breakthrough T1D has released a strategic plan to move cell-based treatments from the lab into clinical trials faster. The roadmap addresses key obstacles that have slowed progress toward regenerative therapies for Type 1 diabetes.
Stem cell treatments are being offered internationally for Type 1 diabetes, but robust scientific evidence about their safety and effectiveness remains limited. Here's what patients and families should consider.
Continuity Biosciences and Breakthrough T1D have partnered to advance the NICHE platform, an implantable technology designed to support pancreatic islet transplantation. The collaboration will support early-stage clinical development of this approach.
The organization formerly known as JDRF supports research across several different approaches—from immune therapies to cell replacement—alongside tools that help people manage diabetes day-to-day.
Over 100 studies on cell therapies, disease-modifying treatments, and diabetes technology will be shared at the ADA's 85th Scientific Sessions in Chicago this June. Breakthrough T1D-funded researchers will showcase progress toward better prevention and treatment options for Type 1 diabetes.
Researchers and clinicians are exploring whether stem cell treatments can repair damage caused by Type 1 diabetes, but questions remain about whether they represent a cure or a repair strategy. A closer look at what stem cells can and cannot do.
Type 1 diabetes changes lives immediately upon diagnosis. Breakthrough T1D, a major research and support organization, offers practical resources and community connection for newly diagnosed patients and longtime living with the condition.
Vice President of Medical Affairs at Breakthrough T1D brings decades of diabetes expertise—from clinical practice to congressional testimony—to the 2026 NorCal Community Summit.
Breakthrough T1D met with EU policymakers to discuss barriers and opportunities for accelerating the development and approval of new therapies, including cell therapies and disease-modifying treatments.